NR1H4 and metabolic dysfunction-associated steatotic liver disease: Several therapeutic approaches for NASH are currently under evaluation including PPARα and FXR agonists.45 Results from the FLINT trial have highlighted OCA as a promising therapeutic agent in NASH17 and Mudaliar et al.46 have documented its efficacy and safety in the treatment of patients with NAFLD and diabetes.